Adimab
Yeast-based antibody discovery and engineering platform
- Sector
- Biotech
- Headquarters
- LEBANON, NH
- Founded
- 2010
- Latest Form D
- $13.8M, Apr 2012
- Total capital
- $13.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $13.8M
- 1 Form D · last Apr 2012
- 175 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 21
- 19 pending · first 2022
- Rank in peer group#8 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$13.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#8 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Bill L. MarisDirectorNamed in SEC Form D filings
- Errik B. AndersonExecutive OfficerNamed in SEC Form D filings
- Fran J. HellerDirectorNamed in SEC Form D filings
- Michael L. RossDirectorNamed in SEC Form D filings
- Robert L. BirnbaumExecutive OfficerNamed in SEC Form D filings
- Terrance L. McGuireDirectorNamed in SEC Form D filings
Show all 8 people
- Tillman U. GerngrossExecutive Officer, DirectorNamed in SEC Form D filings
- William J. MarisDirectorNamed in SEC Form D filings
What it has protected
USPTO · 21 granted of 40- PendingHigh Affinity ANTI-CD3 Antibodies, And Methods For Their Generation And UseUSPTOApplication 19447385
- PendingPh-dependent ANTI-CD3 Antibodies And Methods Relating TheretoUSPTOApplication 19122279
- GrantedHigh Affinity ANTI-CD3 Antibodies, And Methods For Their Generation And UseUSPTOUS 12,552,863
Show all 40 patent records
- High Affinity ANTI-CD3 Antibodies, And Methods For Their Generation And UseJul 23, 2026 · Application 19447385Pending
- Ph-dependent ANTI-CD3 Antibodies And Methods Relating TheretoJun 4, 2026 · Application 19122279Pending
- High Affinity ANTI-CD3 Antibodies, And Methods For Their Generation And UseFeb 17, 2026 · US 12,552,863Granted
- Rationally Designed, Synthetic Antibody Libraries And Uses ThereforJan 20, 2026 · US 12,529,164Granted
- Anti-respiratory Syncytial Virus Antibodies, And Methods Of Their Generation And UseDec 25, 2025 · Application 19083503Pending
- Targeting GDF15-GFRAL PathwayDec 18, 2025 · Application 18722143Pending
- Anti-respiratory Syncytial Virus Antibodies, And Methods Of Their Generation And UseOct 9, 2025 · Application 19014419Pending
- Variant CH3 Domains Engineered For Preferential CH3 Heterodimerization, Multi-specific Antibodies Comprising The Same, And Methods Of Making ThereofJul 10, 2025 · Application 18260808Pending
- Variant CH3 Domains Engineered For Preferential CH3 Heterodimerization, Multi-specific Antibodies Comprising The Same, And Methods Of Making ThereofJul 3, 2025 · Application 18727720Pending
- Antibody LibrariesMay 15, 2025 · Application 18662200Pending
- Anti-respiratory Syncytial Virus Antibodies, And Methods Of Their Generation And UseApr 22, 2025 · US 12,281,156Granted
- Systems And Methods For Intelligent Construction Of Antibody LibrariesApr 17, 2025 · Application 18706089Pending
- Anti-coagulation Factor Xi AntibodiesApr 15, 2025 · US 12,275,800Granted
- Myeloproliferative ConditionsApr 3, 2025 · Application 18834290Pending
- Polyclonal Mixtures Of Antibodies, And Methods Of Making And Using ThemMar 25, 2025 · US 12,258,679Granted
- Anti-respiratory Syncytial Virus Antibodies, And Methods Of Their Generation And UseFeb 4, 2025 · US 12,215,141Granted
- Monoclonal Antibodies And Cocktails For Treatment Of Ebola InfectionsJan 28, 2025 · US 12,209,117Granted
- ANTI-GDF15 Antibodies, Compositions And Uses ThereofJan 16, 2025 · Application 18682205Pending
- Anti-idiotype AntibodiesJan 16, 2025 · Application 18712739Pending
- Multispecific Antibody Analogs Comprising A Common Light Chain, And Methods Of Their Preparation And UseDec 31, 2024 · US 12,180,299Granted
- Polyspecificity Reagents, Methods For Their Preparation And UseDec 31, 2024 · US 12,181,480Granted
- ANTI-CD3 AntibodiesSep 26, 2024 · Application 18692097Pending
- Variant CH1 Domains And Variant Cl Domains Engineered For Preferential Chain Pairing And Multi-specific Antibodies Comprising The SameJul 11, 2024 · Application 18271486Pending
- Antibody LibrariesJun 25, 2024 · US 12,018,403Granted
- ALK7 Binding Proteins And Methods Of Reducing ALK7 Activity Using The SameMay 14, 2024 · US 11,981,738Granted
- Rationally Designed, Synthetic Antibody Libraries And Uses ThereforDec 14, 2023 · Application 17856673Pending
- Antibodies Against BACE1 and Use Thereof for Neural Disease ImmunotherapySep 5, 2023 · US 11,746,160Granted
- CH1 Domain Variants Engineered For Preferential Kappa Light Chain Pairing And Multispecific Antibodies Comprising The SameAug 24, 2023 · Application 17765009Pending
- Anti-coagulation Factor Xi AntibodiesMay 30, 2023 · US 11,661,460Granted
- ANTI-CD3-BINDING Domains And Antibodies Comprising Them, And Methods For Their Generation And UseMay 18, 2023 · Application 18054588Pending
- ANTI-CD3-BINDING Domains And Antibodies Comprising Them, And Methods For Their Generation And UseJan 3, 2023 · US 11,542,330Granted
- Fc Variants With Reduced Effector FunctionDec 15, 2022 · Application 17848808Pending
- Engineered Ph-dependent ANTI-CD3 Antibodies, And Methods For Their Generation And UseDec 1, 2022 · Application 17617019Pending
- Anti-coagulation Factor Xi AntibodiesNov 29, 2022 · US 11,512,142Granted
- Anti-coagulation Factor Xi AntibodiesNov 1, 2022 · US 11,485,794Granted
- Anti-respiratory Syncytial Virus Antibodies, And Methods Of Their Generation And UseNov 1, 2022 · US 11,485,775Granted
- Anti-coagulation Factor Xi AntibodiesOct 25, 2022 · US 11,479,615Granted
- Anti-respiratory Syncytial Virus Antibodies, And Methods Of Their Generation And UseOct 25, 2022 · US 11,479,600Granted
- Monoclonal Antibodies And Cocktails For Treatment Of Ebola InfectionsAug 9, 2022 · US 11,407,816Granted
- Monoclonal Antibodies And Cocktails For Treatment Of Ebola InfectionsAug 9, 2022 · US 11,407,817Granted
Related companies, and why
- Diceros Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- BIOPHY, INC.Similar federal contract value in Biotech · null in contracts
- Deciduous TherapeuticsSimilar federal contract value in Biotech · null in contracts
- AvitideSimilar federal contract value in Biotech · null in contracts
- NEXGENIA, INC.Similar federal contract value in Biotech · null in contracts
- Terremoto BiosciencesSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .